1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Tenitramine Tablets

Trade Name: Tinitran 10
Chemical Family: Mixture
Intended Use: Pharmaceutical product for the treatment of angina pectoris

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenitramine</td>
<td>21946-79-2</td>
<td>Not listed</td>
<td>10 mg***</td>
</tr>
<tr>
<td>Corn Starch</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>*</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>*</td>
</tr>
<tr>
<td>Silicon dioxide, colloidal NF</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
*** per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: White tablets
Signal Word: WARNING

Statement of Hazard: May be harmful if swallowed.

Additional Hazard Information:
Short Term: Accidental ingestion may cause effects similar to those seen in clinical use.
Known Clinical Effects:
Due to intended use, dangerous lowering of blood pressure can occur. Headache, which may be severe and persistent, may occur immediately after use. Vertigo, dizziness, weakness, palpitation, and other manifestations of postural hypotension may develop occasionally. Flushing, drug rash, and exfoliative dermatitis have been reported in patients receiving nitrate therapy.

EU Indication of danger: Harmful
EU Hazard Symbols:
EU Risk Phrases: R22 - Harmful if swallowed.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing.

Storage Conditions: No special precautions required.
Material Name: Tenitramine Tablets
Revision date: 04-Jan-2007

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with large quantities.
Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.
Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities.
Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

Microcrystalline cellulose

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total
ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA
Australia TWA = 10 mg/m³ TWA

Silicon dioxide, colloidal NF

OSHA - Final PELs - Table Z-3 Mineral D: (80)/(% SiO2) mg/m³ TWA = 20 mppcf TWA
Australia TWA = 2 mg/m³ TWA

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: None
Incompatible Materials: None

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Microcrystalline cellulose
Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose
- Skin Irritation: Rabbit, Non-irritating
- Eye Irritation: Rabbit, Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Tenitramine
- 6 Month(s) - Rat, Oral, 2 mg/kg/day NOAEL, None identified
- 6 Month(s) - Rabbit, Oral, 0.5 mg/kg/day NOAEL, None identified

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Tenitramine
- Fertility and Embryonic Development: Mouse, Oral, 0.5 mg/kg/day NOEL, No effects at maximum dose
- Fertility and Embryonic Development: Rat, Oral, 0.5 mg/kg/day NOEL, No effects at maximum dose
- Fertility and Embryonic Development: Rabbit, Oral, 0.5 mg/kg/day NOEL, No effects at maximum dose

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Silicon dioxide, colloidal NF
- IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

EU Symbol: Xn
EU Indication of danger: Harmful

EU Risk Phrases: R22 - Harmful if swallowed.

EU Safety Phrases: S22 - Do not breathe dust.

OSHA Label:
WARNING
May be harmful if swallowed.

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 1, Subdivision B

Corn Starch
Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present
EU EINECS List 232-679-6

Microcrystalline cellulose
Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present
EU EINECS List 232-674-9

Silicon dioxide, colloidal NF
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS List 231-545-4

16. OTHER INFORMATION

Reasons for Revision: Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.
End of Safety Data Sheet